GlassScriptPhysician profile
Hninyee A Win
NPI 1588154892
$1,106.56
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $114 · 2022: $157 · 2023: $200 · 2024: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $481 · Education: $354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $480.69 |
| Education | $353.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $160.98 | 2022-2024 | |
| Daiichi Sankyo INC. | $158.92 | 2023-2024 | Enhertu |
| Incyte Corporation | $147.10 | 2023-2024 | Jakafi, Monjuvi |
| Sobi, INC | $115.81 | 2024 | |
| Stemline Therapeutics INC. | $114.43 | 2021 | |
| Genzyme Corporation | $104.22 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $100.68 | 2024 | Lynparza, Enhertu |
| Pharmacosmos Therapeutics INC. | $91.38 | 2024 | Cosela |
| Genentech USA, INC. | $52.67 | 2024 | Phesgo, Perjeta |
| Sumitomo Pharma America, INC. | $25.78 | 2024 | Orgovyx |
| Gilead Sciences, INC. | $19.05 | 2023 | |
| Novartis Pharmaceuticals Corporation | $15.54 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hninyee Win listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.